











































High-sensitivity cardiac troponin and the early rule out of
myocardial infarction: time for action
Citation for published version:
Chapman, AR & Mills, NL 2020, 'High-sensitivity cardiac troponin and the early rule out of myocardial
infarction: time for action', Heart, pp. heartjnl-2020-316811. https://doi.org/10.1136/heartjnl-2020-316811
Digital Object Identifier (DOI):
10.1136/heartjnl-2020-316811
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
  1Chapman AR, Mills NL. Heart Month 2020 Vol 0 No 0
High- sensitivity cardiac troponin and 
the early rule out of myocardial 
infarction: time for action
Andrew R Chapman   , Nicholas L Mills   
Chest pain is one of the most frequent 
presenting complaints in patients attending 
the emergency department, with almost 1 
million attendances across the UK every 
year.1 The priority of the attending clini-
cian is to promptly reach a diagnosis, as 
early intervention with medical therapy 
has been shown to reduce morbidity and 
mortality in patients with myocardial 
infarction. However, as few as 1 in 10 
patients with chest pain actually have a 
diagnosis of myocardial infarction, with 
the majority presenting due to alternative 
diagnoses. Therefore, the safe and early 
rule out of myocardial infarction may be 
helpful by facilitating a refocused clinical 
evaluation, with targeted investigations 
for alternative differential diagnoses. This 
can also provide confidence that patients 
with typical anginal symptoms have not 
had myocardial infarction and may be 
safely triaged for outpatient investigation.
High- sensitivity cardiac troponin assays 
were first introduced across Europe and 
Australasia in 2010. There are now several 
high- sensitivity assays available for use, all 
of which offer a magnitude improvement 
in performance over the previous gener-
ation. A number of diagnostic algorithms 
have been written which exploit the 
performance of these assays for detection 
of cardiac troponin at low concentration. 
For example, in patients with suspected 
acute coronary syndrome with a non- 
ischaemic ECG and a high- sensitivity 
cardiac troponin I or T concentration <5 
ng/L (measured using the Abbott ARCHI-
TECT or Siemens Atelleca hs- cTnI, or the 
Roche Elecsys hs- cTnT assays), both nega-
tive predictive value and sensitivity are 
extremely high, missing as few as 1 in every 
200 patients tested and stratifying between 
30% and 50% of patients as low risk.2–4 
The High- Sensitivity Cardiac Troponin 
on Presentation to Rule- Out Myocardial 
Infarction (HiSTORIC) trial evaluated 
this approach in a stepped- wedge cluster 
randomised controlled trial, reporting at 
the European Society of Cardiology (ESC) 
Congress in 2019, demonstrating imple-
mentation of an early rule- out pathway 
for myocardial infarction reduced length 
of stay and hospital admission without 
increasing adverse cardiac events.
The ESC 0/1 hour algorithm is one 
approach to the risk stratification of 
patients with suspected acute coronary 
syndrome. In this pathway, patients 
without ischaemia on the ECG are strat-
ified based on their presentation and 1 
hour troponin concentrations using assay- 
specific thresholds. In patients with very 
low troponin concentrations below the 
‘rule- out’ threshold with at least 3 hours 
of symptoms, myocardial infarction is 
immediately ruled out on a single test. In 
those with troponin concentrations above 
a predefined ‘rule- in’ threshold, the likeli-
hood of myocardial infarction is high, and 
patients are admitted for investigation and 
treatment. In all others, repeat troponin 
testing is performed at 1 hour after the 
initial sample to detect small but important 
rises in cardiac troponin concentration. If 
on serial testing the rule- in or rule- out 
thresholds are not reached, patients are 
observed for myocardial ischaemia and 
should undergo peak troponin testing to 
guide decision making.
Chiang et al5 present findings from a 
systematic review and meta- analysis of 
studies evaluating the performance of the 
ESC 0/1 hour algorithm in patients with 
suspected acute coronary syndrome. They 
included 11 014 patients from 15 studies 
and 10 individual cohorts across Europe, 
the USA, Japan, Thailand and China, 
employing bivariate random- effects meth-
odology for a primary outcome of index 
myocardial infarction and secondary 
outcome of major adverse cardiac event or 
death from any cause.
The authors found similar diagnostic 
performance across three commercially 
available high- sensitivity cardiac troponin 
assays for the exclusion of index myocar-
dial infarction. The Roche hs- cTnT assay 
identified 55% of patients as low risk, 
with a pooled sensitivity of 98.4% (95% 
CI 95.1% to 99.5%) and negative predic-
tive value (NPV) of 100% (95% CI 99.9% 
to 100%). The Abbott hs- cTnI assay 
identified 50% as low risk, with a sensi-
tivity and NPV of 98.1% (95% CI 94.6% 
to 99.3%) and 99% (95% CI 96.0% to 
100%), and the Siemens hs- cTnI assay 
identified 51% of patients as low risk, 
with a sensitivity and NPV of 98.7% (95% 
CI 97.3% to 99.3%) and 100% (95% CI 
99% to 100%). In patients triaged to rule 
out, the mortality at 30 days and at 1 year 
was low, at 0.1% (95% CI 0.0% to 0.4%) 
and 0.8% (95% CI 0.5% to 1.2%), respec-
tively (figure 1).
The rule- in performance of the ESC 
0/1 hour algorithm was also evaluated. 
The Roche hs- cTnT assay ruled in 18% 
of patients with a positive predictive 
value (PPV) of 51% (95% CI 31% to 
71%), whereas the Siemens hs- cTnI assay 
ruled in 14% of patients with a PPV of 
73% (95% CI 69% to 77%). As only 
two studies evaluated the performance of 
the Abbott hs- cTnI for rule in, no meta- 
estimates were obtained.
Notably, the proportion of patients 
triaged towards the observation zone 
differed markedly across cohorts, from 
22.4% (TRAPID Cohort; Roche hs- cTnT) 
to 37.1% (HIGH- US Cohort; Siemens 
hs- cTnI). Patients in this category were 
at high risk of adverse outcomes. In a 
secondary analysis evaluating the future 
risk of MACE or death, at 30 days, the 
pooled event rate for patients in the obser-
vation zone was equivalent to the event 
rate in the rule- out population at 1 year 
(event rate 0.7%, 95% CI 0.3% to 1.2% 
in the observation group at 30 days vs 
event rate 0.8%, 95% CI 0.6% to 1.0%). 
Furthermore, at 1 year, the event rate in 
patients within the observation zone was 
equivalent to those who were ruled in with 
a high probability of myocardial infarction 
(event rate 8.1%, 95% CI 6.1% to 10.4% 
in the observation group vs 10%, 95% CI 
7.8% to 12.4% in the rule- in group).
This analysis provides important insights 
into the performance of the ESC 0/1 hour 
algorithm across different healthcare 
settings. There are several strengths. The 
authors conducted a systematic review and 
included only prospective cohort studies 
in patients presenting to the emergency 
department with suspected acute coronary 
syndrome, where high- sensitivity cardiac 
troponin concentrations were measured 
using a commercially available assay, and 
the diagnosis of myocardial infarction was 
adjudicated according to the Universal 
Definition. The prevalence of myocar-
dial infarction varied from 2% (Parkland, 
USA) to 32% (Beijing, China). Where 
multiple publications emerged from the 
same cohorts, the authors included the 
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study with the largest sample size or most 
complete dataset.
As with all meta- analyses there are some 
limitations. First, studies did not use iden-
tical criteria for recruitment, with some 
cohorts excluding patients with missing 1 
hour samples, or those with comorbidity 
such as end- stage renal failure. Second, 
some cohorts evaluated the ESC 0/1 hour 
algorithm against an outcome including 
a diagnosis of type 2 myocardial infarc-
tion. Type 2 myocardial infarction occurs 
in the context of another acute illness 
where there is myocardial oxygen supply 
or demand imbalance. These patients are 
by definition unwell and require hospi-
talisation for assessment and treatment, 
and in clinical practice are not consid-
ered for discharge. Pathways such as the 
ESC algorithm were not intended for this 
purpose. Third, the authors did not have 
access to individual patient- level data, and 
while the ESC guidelines state this algo-
rithm should only be applied in patients 
without myocardial ischaemia on the 
ECG, all cohorts did not necessarily apply 
these criteria, and this may have adversely 
affected performance. Fourth, the authors 
included patients within the original ESC 
0/1 hour algorithm derivation cohorts in 
some analyses. They attempted to mitigate 
for this by conducting a sensitivity analysis 
with these cohorts excluded, and diag-
nostic performance was similar to overall 
estimates. Finally, all patients included in 
this meta- analysis were recruited as part 
of observational cohort studies, where 
management was not guided by the 
ESC 0/1 hour algorithm, and individual 
management decisions may have influ-
enced patient outcomes.
Overall, the authors conclude that the 
ESC 0/1 hour algorithm may not have 
the required diagnostic performance if a 
sensitivity of 99% is mandated, but is this 
truly required in practice? Very few tests 
in clinical practice have achieved such a 
goal. There are strengths and limitations 
of using either sensitivity or NPV as the 
primary safety metric, but in the majority 
of cohorts, the ESC 0/1 hour algorithim 
performed very well. Study- specific factors 
may well have influenced the performance 
observed in the two cohorts which were 
outliers (Barcelona cohort; sensitivity 
88%, 95% CI 68.8% to 97.5%, NPV 
96.9%, 95% CI 91.2% to 99.4%; Beijing 
cohort; sensitivity 92.3%, 95% CI 84.8% 
to 96.9%, NPV 91.3%, 95% CI 82.8% to 
96.4%).
Notably, the ESC 0/1 hour algorithm 
has already been evaluated in a prospec-
tive randomised controlled trial.6 Chew 
et al randomly assigned 3378 patients 
with suspected acute coronary syndrome 
to either the ESC 0/1 hour hs- cTnT 
pathway, or a standard care arm using 
hs- cTnT at the 99th centile. They demon-
strated an increased rate of discharge 
from the emergency department with 
the 0/1 hour algorithm (45.1% vs 
32.3%, p<0.001) and a reduced length 
of stay (4.6, IQR (3.4–6.4) hours vs 5.6 
(4.0–7.1) hours, p<0.001). The ESC 0/1 
hour pathway had an overall NPV of 
99.6% (99.0%–99.9%) for 30- day death 
or myocardial infarction, and was non- 
inferior to standard care. Similar find-
ings were observed in a non- randomised, 
prospective international multicentre 
implementation study by Twerenbold 
et al.7 In 2296 patients with suspected 
acute coronary syndrome, the ESC 0/1 
hour algorithm was followed in 94% of 
cases, with a median length of stay 2.5 
(2.3–4.0) hours. The majority of patients 
(62%) were ruled out in the emergency 
department, with just 0.2% (3/1420) of 
patients experiencing a major adverse 
cardiovascular event at 30 days.
There are a number of well- validated 
approaches which apply cardiac troponin 
as a continuous variable, all of which offer 
a magnitude improvement in safety over 
those using troponin as a binary variable 
at the 99th centile.8–10 There are strengths 
and limitations of each, but the choice of 
algorithm is best determined at a local 
level in conjunction with both the clin-
ical and laboratory service. The decision 
to admit or discharge will always be taken 
by a physician using all available clinical 
information, including the ECG, results 
from other investigations and the pres-
ence of ongoing symptoms. While path-
ways do simplify decision making, they do 
not replace clinical judgement, and a final 
diagnosis should always be sought.
It is difficult to overlook the extreme 
pressures that healthcare systems world-
wide are currently experiencing as a result 
of the Coronavirus pandemic. While many 
emergency departments will already have 
implemented rapid rule- out pathways for 
acute myocardial infarction, some have 
not, particularly those in the USA. There 
is a plethora of data evaluating high- 
sensitivity troponin testing in patients 
with suspected acute coronary syndrome, 
including two prospective, randomised 
controlled trials, demonstrating very low 
rates of future myocardial infarction or 
death as far as 1 year after index presenta-
tion. It is time to take advantage of these 
strategies to reduce overcrowding, miti-
gate the associated risks of hospitalisation 
and prevent harm.
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Figure 1 Comparison of the performance of the European Society of Cardiology (ESC) Congress 
0/1 hour algorithm for the rule out of index myocardial infarction across three high- sensitivity 
cardiac troponin assays. Note no meta- estimates were obtained for either rule- in or observational 
zone performance using the Abbott hs- cTnl assay due to insufficient study numbers. NPV, negative 
predictive value.
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